Valuation: SciSparc Ltd.

Market Cap 2.87M 2.52M 2.35M 2.16M 4.05M 275M 4.11M 27.94M 10.91M 136M 10.78M 10.55M 470M P/E 2024
-0.33x
P/E 2025 -0.12x
Enterprise Value -1.35M -1.19M -1.11M -1.02M -1.91M -130M -1.93M -13.16M -5.14M -64.07M -5.08M -4.97M -221M EV / Sales 2024
-551,308x
EV / Sales 2025 289,759x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day-6.00%
1 week+6.60%
Current month-9.24%
1 month-12.11%
3 months-42.61%
6 months-36.75%
Current year-59.07%
1 week 4.6
Extreme 4.6
6.46
1 month 4.23
Extreme 4.23
6.46
Current year 2.98
Extreme 2.98
15.79
1 year 2.98
Extreme 2.98
80.1
3 years 2.98
Extreme 2.98
2,997.05
5 years 0.49
Extreme 0.4914
41,769.08
10 years 0.49
Extreme 0.4914
41,769.08
Manager TitleAgeSince
Chief Executive Officer 39 10/01/2022
Chief Executive Officer 62 21/08/2020
Chief Tech/Sci/R&D Officer 56 08/02/2016
Director TitleAgeSince
Chairman 62 10/01/2022
Chairman 79 21/09/2025
Director/Board Member 50 21/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
-6.00%+6.60%-92.33%-99.80% 3.06M
+1.68%+0.88%+16.17%+73.90% 48.36B
-0.57%+1.67%+60.70%+109.11% 35.8B
-0.09%-2.23%-8.03%+20.31% 11.83B
-0.05%-3.55%+13.50%+70.62% 11.48B
-0.37%0.00%+37.53%+136.73% 9.01B
-0.49%+1.38%+46.83%-6.77% 6.99B
+0.95%-1.59%+12.78%+32.81% 6.7B
+0.18%-1.94%+2.36%+167.04% 6.42B
+3.51%-10.69%-31.55%+1.09% 5.3B
Average -0.11%-0.43%+5.79%+50.50% 14.19B
Weighted average by Cap. +0.57%-0.14%+25.47%+77.62%

Financials

2024 2025
Net sales 1.31 1.15 1.07 0.98 1.84 125.24 1.87 12.7 4.96 61.84 4.9 4.8 213.75 0.86 0.75 0.7 0.64 1.21 82.09 1.22 8.33 3.25 40.53 3.21 3.14 140.1
Net income -6.28M -5.52M -5.14M -4.72M -8.87M -603M -8.98M -61.12M -23.87M -298M -23.59M -23.08M -1.03B -12.18M -10.71M -9.97M -9.15M -17.19M -1.17B -17.41M -118M -46.27M -577M -45.72M -44.73M -1.99B
Net Debt -2.01M -1.77M -1.65M -1.51M -2.84M -193M -2.88M -19.56M -7.64M -95.23M -7.55M -7.39M -329M -4.22M -3.71M -3.46M -3.18M -5.96M -405M -6.04M -41.1M -16.05M -200M -15.86M -15.52M -692M
Logo SciSparc Ltd.
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Employees
3
Date Price Change Volume
27/07/26 $5.010 -6.00% 84,113
24/07/26 $5.330 -6.82% 11,703
23/07/26 $5.720 +18.18% 83,783
22/07/26 $4.840 +1.89% 10,988
21/07/26 $4.750 +1.06% 10,980

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRC Stock